{
    "cancer_info": {
        "cancer_name": "Breast Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Gynecologic assessment (baseline and annual)",
            "Bone mineral density scan (DEXA)",
            "Mammographic breast density assessment (BI-RADS)",
            "Genetic testing (BRCA1/2, TP53, PTEN, CDH1, STK11)",
            "Annual bilateral mammography (± tomosynthesis)",
            "Clinical breast exam every 6–12 months",
            "Breast MRI for high-risk individuals",
            "Transvaginal ultrasound",
            "Office endometrial biopsy",
            "Screening for Factor V Leiden/prothrombin mutations",
            "Genetic counseling",
            "BRCA1/2 testing"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Gail 5-year risk ≥1.7% or Tyrer-Cuzick 10-year risk ≥5%",
            "risk_group": "High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Premenopausal women",
                    "plan_name": "Tamoxifen",
                    "plan_details": "20 mg/day for 5 years (49% risk reduction in invasive breast cancer)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Postmenopausal women",
                    "plan_name": "Tamoxifen",
                    "plan_details": "20 mg/day for 5 years",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Postmenopausal women",
                    "plan_name": "Raloxifene",
                    "plan_details": "60 mg/day for 5 years (38-44% risk reduction)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Postmenopausal women",
                    "plan_name": "Aromatase Inhibitors",
                    "plan_details": "Exemestane 25 mg/day or Anastrozole 1 mg/day for 5 years (53-65% risk reduction)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Alternative regimen",
                    "patient_subgroup": "Symptomatic/intolerant patients",
                    "plan_name": "Low-dose Tamoxifen",
                    "plan_details": "5 mg/day or 10 mg every other day for 3-5 years",
                    "nccn_evidence_category": "Not specified",
                    "nccn_recommendation_category": "Other regimen"
                }
            ]
        },
        {
            "staging_criteria": "BRCA1/2, TP53, PTEN mutations; Lifetime risk >20-25%",
            "risk_group": "Very High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Mutation carriers",
                    "plan_name": "Risk-reducing mastectomy (RRM)",
                    "plan_details": "90-95% risk reduction with immediate reconstruction",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "BRCA1/2 carriers",
                    "plan_name": "Risk-reducing salpingo-oophorectomy (RRSO)",
                    "plan_details": "50% breast cancer risk reduction",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "History of atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS)",
            "risk_group": "Special High-Risk Subgroup",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "AH/LCIS patients",
                    "plan_name": "Endocrine agents",
                    "plan_details": "86% risk reduction for AH, 50% for LCIS",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "BRCA1/2 mutations: Higher benefit from RRM; tamoxifen more effective for BRCA2 carriers (ER+ tumors); ER status: All risk-reducing agents target ER+ cancers (no benefit for ER-); CYP2D6 polymorphisms: Poor metabolizers have reduced tamoxifen efficacy; avoid strong CYP2D6 inhibitors; Hot flashes: Biomarker for tamoxifen bioavailability; Factor V Leiden/prothrombin mutations: Increase VTE risk with tamoxifen; Vitamin D/carotenoids: Lower levels correlate with increased breast cancer risk"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：降低乳腺癌风险.txt"
}